- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07518914
Beskyttelse mot Feilinformasjon om Lenakapavir blant Unge Kvinner i Gauteng, Sør-Afrika (PROTECT-L) (PROTECT-L)
Beskyttelse mot feilinformasjon om lenacapavir blant unge kvinner i Gauteng, Sør-Afrika
Adolescent girls and young women (AGYW) in South Africa remain disproportionately affected by HIV, with prevalence among 15-24-year-olds at 9.4% in 2024 despite expanded access to condoms, HIV testing, and oral PrEP. While oral PrEP is effective, its reliance on daily adherence and regular follow-up has limited impact for many young women. Lenacapavir (LEN), the first long-acting injectable PrEP administered twice yearly, offers a promising alternative that could improve persistence and protection. However, LEN's potential may be undermined by misinformation, particularly around safety and trust, which has been shown in other HIV prevention contexts to reduce uptake and demand. Proactive strategies, such as psychological inoculation, are therefore needed to prebunk misinformation and support future LEN implementation among AGYW.
Primary objective: To compare changes in intentions to receive Lenacapavir following misinformation exposure in groups with and without psychological inoculation and behavioural economics boost.
Secondary objectives: (1) To compare believability and persuasiveness of misinformation claims and motivational threat associated with misinformation in groups with and without psychological inoculation and behavioural economics boost. (2) To explore subgroup effects by relevant sociodemographic and behavioural factors including HIV risk, PrEP history, COVID-19 vaccine history, general vaccine hesitancy, and information avoidance. The investigators will conduct a two-arm randomized controlled trial of 2-3 inoculation messages that address emerging myths and misinformation about Lenacapavir in South Africa. Participants will be randomly assigned to a control group or an intervention arm: enhanced inoculation message with insights from behavioural economics.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Teniola Egbe, MPH, MBE
- Telefonnummer: 215-898-2939
- E-post: tegbe@pennmedicine.upenn.edu
Studer Kontakt Backup
- Navn: Alison Buttenheim, PhD
- E-post: butt@nursing.upenn.edu
Studiesteder
-
-
-
Johannesburg, Sør-Afrika
- Rekruttering
- Health Economics and Epidemiology Research Office, University of the Witwatersrand
-
Ta kontakt med:
- Candice Chetty-Makkan, PhD
- Telefonnummer: +27 (0) 10 001 7941
- E-post: cchetty@heroza.org
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Female (cisgender or transgender)
- Age 18-29 years
- Self-reported history of sexual activity in the past 12 months
- Self-reported HIV-negative status or unknown HIV status at enrolment
- Willing and able to provide consent
- Able to read and understand English
Exclusion Criteria:
Unwilling or unable to provide consent for study participation.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Control
Participants enrolled in the control group will receive unrelated information on diabetes and nutrition topics of the same length as the inoculation messages. Please see Appendix 6 for an example of how this message will be structured. This will make the control group an attention control group and ensure that findings are not confounded by the intervention group spending more time and attentional resources on participation in the study |
Participants enrolled in the control group will receive unrelated information on diabetes topics of the same length as the inoculation messages. Please see Appendix 6 for an example of how this message will be structured. This will make the control group an attention control group and ensure that findings are not confounded by the intervention group spending more time and attentional resources on participation in the study |
|
Annen: Enhanced inoculation message
Participants enrolled in the enhanced inoculation message arm will receive messages that warn them about impendingLlenacapavir misinformation and explains why those claims are false or misleading, the messages will be enhanced with insights from behavioural economics see Appendix 5: "Inoculation message with a BE boost" for an example of the inoculation message. As part of the behavioural economics boost, participants may choose to receive a small token (e.g., sticker, badge, bracelet) with a message promoting vaccination as a consistency and commitment prime |
Participants enrolled in the enhanced inoculation message arm will receive messages that warn them about impending Lenacapavir misinformation and explains why those claims are false or misleading, the messages will be enhanced with insights from behavioural economics see Appendix 5: "Inoculation message with a BE boost" for an example of the inoculation message. As part of the behavioural economics boost, participants may choose to receive a small token (e.g., sticker, badge, bracelet) with a message promoting vaccination as a consistency and commitment prime. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Lenacapavir intention, at the end of the baseline assessment
Tidsramme: At the end of the baseline assessment
|
Intention to get the Lenacapavir, measured after inoculation intervention and misinformation exposure The intention to get Lenacapavir will be measured on a 1-10 scale. Higher score meaning you are extremely likely to do the action. |
At the end of the baseline assessment
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Lenacapavir intention, follow-up
Tidsramme: 2-4 weeks
|
Intention to get Lenacapavir, measured at follow-up survey following misinformation exposure and intervention. Measured on a 1-10 scale. Higher score meaning you are extremely likely to do the action. |
2-4 weeks
|
|
Recommend to friends, at the end of the baseline assessment
Tidsramme: At the end of the baseline assessment
|
Intention to recommend Lenacapavir to friends, measured at survey baseline following misinformation exposure and intervention. Measured on a 1-10 scale. Higher score meaning you are extremely likely to do the action. |
At the end of the baseline assessment
|
|
Recommend to friends, follow-up
Tidsramme: 2-4 weeks
|
Intention to recommend Lenacapavir to friends, measured at follow-up survey following misinformation exposure and intervention, controlling for baseline pre-intervention/exposure intention. Measured on a 1-10 scale. Higher score meaning you are extremely likely to do the action. |
2-4 weeks
|
|
Credibility of inoculated exposure #1
Tidsramme: At the end of the baseline assessment
|
Extent to which the claim is credible, extent to which the claim makes you anxious or nervous about Lenacapavir, likelihood of your sharing the claim, for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you believe the claim is real. |
At the end of the baseline assessment
|
|
Credibility of inoculated exposure #2
Tidsramme: At the end of the baseline assessment
|
Extent to which the claim is credible, extent to which the claim makes you anxious or nervous about Lenacapavir, likelihood of your sharing the claim, for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you believe the claim is real. |
At the end of the baseline assessment
|
|
Credibility of inoculated exposure #3
Tidsramme: At the end of the baseline assessment
|
Extent to which the claim is credible, extent to which the claim makes you anxious or nervous about Lenacapavir, likelihood of your sharing the claim, for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you believe the claim is real. |
At the end of the baseline assessment
|
|
Credibility of inoculated exposure #4
Tidsramme: At the end of the baseline assessment
|
Extent to which the claim is credible, extent to which the claim makes you anxious or nervous about Lenacapavir, likelihood of your sharing the claim, for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you believe the claim is real. |
At the end of the baseline assessment
|
|
Credibility of inoculated exposure #5
Tidsramme: At the end of the baseline assessment
|
Extent to which the claim is credible, extent to which the claim makes you anxious or nervous about Lenacapavir, likelihood of your sharing the claim, for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you believe the claim is real. |
At the end of the baseline assessment
|
|
Credibility of inoculated exposure #6
Tidsramme: At the end of the baseline assessment
|
Extent to which the claim is credible, extent to which the claim makes you anxious or nervous about Lenacapavir, likelihood of your sharing the claim, for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you believe the claim is real. |
At the end of the baseline assessment
|
|
Credibility of inoculated exposure #7,follow-up
Tidsramme: 2-4 weeks
|
Extent to which the claim is credible, extent to which the claim makes you anxious or nervous about Lenacapavir, likelihood of your sharing the claim, for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you believe the claim is real. |
2-4 weeks
|
|
Credibility of inoculated exposure #8,follow-up
Tidsramme: 2-4 weeks
|
Extent to which the claim is credible, extent to which the claim makes you anxious or nervous about Lenacapavir, likelihood of your sharing the claim ,for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you believe the claim is real. |
2-4 weeks
|
|
Credibility of inoculated exposure #9,follow-up
Tidsramme: 2-4 weeks
|
Extent to which the claim is credible, extent to which the claim makes you anxious or nervous about Lenacapavir, likelihood of your sharing the claim, for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you believe the claim is real. |
2-4 weeks
|
|
Credibility of inoculated exposure #10,follow-up
Tidsramme: 2-4 weeks
|
Extent to which the claim is credible, extent to which the claim makes you anxious or nervous about Lenacapavir, likelihood of your sharing the claim, for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you believe the claim is real. |
2-4 weeks
|
|
Anxiousness of inoculated exposure #1
Tidsramme: At the end of the baseline assessment
|
Extent to which the claim makes you anxious or nervous about lenacapavir for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means the claim makes you anxious or worried. |
At the end of the baseline assessment
|
|
Anxiousness of inoculated exposure #2
Tidsramme: At the end of the baseline assessment
|
Extent to which the claim makes you anxious or nervous about lenacapavir for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means the claim makes you anxious or worried. |
At the end of the baseline assessment
|
|
Anxiousness of inoculated exposure #3
Tidsramme: At the end of the baseline assessment
|
Extent to which the claim makes you anxious or nervous about lenacapavir for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means the claim makes you anxious or worried. |
At the end of the baseline assessment
|
|
Anxiousness of inoculated exposure #4
Tidsramme: At the end of the baseline assessment
|
Extent to which the claim makes you anxious or nervous about lenacapavir for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means the claim makes you anxious or worried. |
At the end of the baseline assessment
|
|
Anxiousness of inoculated exposure #5
Tidsramme: At the end of the baseline assessment
|
Extent to which the claim makes you anxious or nervous about lenacapavir for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means the claim makes you anxious or worried. |
At the end of the baseline assessment
|
|
Anxiousness of inoculated exposure #6
Tidsramme: At the end of the baseline assessment
|
Extent to which the claim makes you anxious or nervous about lenacapavir for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means the claim makes you anxious or worried. |
At the end of the baseline assessment
|
|
Anxiousness of inoculated exposure #7,follow-up
Tidsramme: 2-4 weeks
|
Extent to which the claim makes you anxious or nervous about lenacapavir for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means the claim makes you anxious or worried. |
2-4 weeks
|
|
Anxiousness of inoculated exposure #8,follow-up
Tidsramme: 2-4 weeks
|
Extent to which the claim makes you anxious or nervous about lenacapavir for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means the claim makes you anxious or worried. |
2-4 weeks
|
|
Anxiousness of inoculated exposure #9,follow-up
Tidsramme: 2-4 weeks
|
Extent to which the claim makes you anxious or nervous about lenacapavir for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means the claim makes you anxious or worried. |
2-4 weeks
|
|
Anxiousness of inoculated exposure #10,follow-up
Tidsramme: 2-4 weeks
|
Extent to which the claim makes you anxious or nervous about lenacapavir for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means the claim makes you anxious or worried. |
2-4 weeks
|
|
Shareability of inoculated exposure #1
Tidsramme: At the end of the baseline assessment
|
Likelihood of your sharing the claim for for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you are more likely to share the claim. |
At the end of the baseline assessment
|
|
Shareability of inoculated exposure #2
Tidsramme: At the end of the baseline assessment
|
Likelihood of your sharing the claim for for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you are more likely to share the claim. |
At the end of the baseline assessment
|
|
Shareability of inoculated exposure #3
Tidsramme: At the end of the baseline assessment
|
Likelihood of your sharing the claim for for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you are more likely to share the claim. |
At the end of the baseline assessment
|
|
Shareability of inoculated exposure #4
Tidsramme: At the end of the baseline assessment
|
Likelihood of your sharing the claim for for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you are more likely to share the claim. |
At the end of the baseline assessment
|
|
Shareability of inoculated exposure #5
Tidsramme: At the end of the baseline assessment
|
Likelihood of your sharing the claim for for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you are more likely to share the claim. |
At the end of the baseline assessment
|
|
Shareability of inoculated exposure #6
Tidsramme: At the end of the baseline assessment
|
Likelihood of your sharing the claim for for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you are more likely to share the claim. |
At the end of the baseline assessment
|
|
Shareability of inoculated exposure #7,follow-up
Tidsramme: 2-4 weeks
|
Likelihood of your sharing the claim for for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you are more likely to share the claim. |
2-4 weeks
|
|
Shareability of inoculated exposure #8,follow-up
Tidsramme: 2-4 weeks
|
Likelihood of your sharing the claim for for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you are more likely to share the claim. |
2-4 weeks
|
|
Shareability of inoculated exposure #9,follow-up
Tidsramme: 2-4 weeks
|
Likelihood of your sharing the claim for for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you are more likely to share the claim. |
2-4 weeks
|
|
Shareability of inoculated exposure #10,follow-up
Tidsramme: 2-4 weeks
|
Likelihood of your sharing the claim for for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you are more likely to share the claim. |
2-4 weeks
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 859478
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
The investigators are still determining the data sharing plan and if we will be sharing IPD yet
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .